![Artwork for Signals From [Space]](https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F55686857-6b99-45a6-ac0f-09c9f023f2a0_500x500.png)
Signals From [Space]
Tim Fitzpatrick, Bethany Keith, John E Milad, Michael Serle DMSc., MS, PA-C, Eric Schlorff, Alex Hassan, David Narrow, Alice Wei, MD, Lilian OkonkwoIdeas, innovations, & investments shaping the future of global kidney health
| Platform |  | Pricing | Freemium |
|---|---|---|---|
| Publishes | Twice weekly | Issues | 96 |
| Subscribers | Read | trfitzpatrick.com |
Curious about how many subscribers Signals From [Space] has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over three million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Chart Rankings
How this newsletter ranks in the official Substack charts.
| #237 |
Latest Issues
Recent posts by this newsletter. Browse the email archive.
Signals Brief: DaVita Earnings in Q4 2024
Earnings, Cost Pressures, and the Road Ahead: IKC Expansion, Helene’s Impact, Year-over-year Comps, and the Oral Drug Reimbursement Shift
Signals Recap: Humana-Monogram, FDA Approves Xeno Trials, Travere Targets FSGS, National Donor Day, & More...
Welcome back. The kidneyverse has been buzzing with major developments these past two weeks, both in headlines and behind the scenes. That’s why we’re here—to bring you up to speed and open the floor for discussion.
KCC in Numbers: What We Know, What We Don't, and What Comes Next
The Kidney Care Choices (KCC) Model is the closest iteration toward value-based kidney care we’ve seen, but understanding its true impact requires more than raw numbers or anecdotes—it requires a clear, visual benchmark.
Signals Recap: Ozempic's Latest Approval, EKDA on Reddit, Lilly Stops Relaxin, Beta Bionics IPO, NKF Turns 75, & More...
We’re back in action with another Sunday batch of headlines, research, community updates and open roles across the Kidneyverse. Welcome to the 192 new subscribers who joined us last month to shape the future of global kidney health.
Similar Newsletters
Other publications recommended by the authors of this newsletter.
Authors
The writers behind this newsletter.
Serial founder and veteran who enjoys writing about the people, companies & ideas shaping the future. Send me your best science, fiction, & sci-fi recs.
Bethany is the registered dietitian for Renal Care 360°, where she is working on expanding access to Medical Nutrition Therapy through the development of targeted programs and services.
I have 25 years’ experience as an executive leader, entrepreneur and venture capitalist building successful healthcare startups on both sides of the Atlantic.
Passionate clinician and medical/clinical affairs professional with over 20 years of dedicated commitment to the kidney community. Currently, I am the Clinical Director, Home Therapies, for Mozarc Medical’s Global Medical and Clinical Affairs team.
Member of SeaStar Medical's Executive Team, focused on changing how inflammation is treated in acute and chronic indications
Healthcare, tech, and everything inbetween. New product development, robotics, AI, and improving access to care via technology.
Former biomedical engineer and healthcare strategy consultant turned medical device entrepreneur.
A seasoned kidney doctor and healthcare leader, driven by curiosity and a deep commitment to serve. Inspired by patients and innovations in health technology, with 20 years of expertise in advancing care and outcomes.
Meet Lilian Okonkwo: Healthcare Superhero! When I’m not saving lives as a senior nurse leader and nephrology consultant, I’m juggling two boys and the chaos of family life! Passionate about health equity and innovation—let’s make healthcare fun!
Frequently Asked Questions
How can I access the email archive for Signals From [Space]?
You can find recent issues that have been published by Signals From [Space] on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Signals From [Space] have?
To see how many people subscribe to Signals From [Space], simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Signals From [Space]?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Signals From [Space] as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Signals From [Space]?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Signals From [Space] using the contact information provided and ask for a copy of their media kit.
How can I find newsletters similar to Signals From [Space]?
Scroll up to where it says Similar Newsletters to see other publications like Signals From [Space]. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Signals From [Space]?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.